BMRN Q1 2022 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q1 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$519M+6.9% YoY

Gross Profit

$402M77.5% margin

Operating Income

$137M26.4% margin

Net Income

$121M23.3% margin

EPS (Diluted)

$0.62

QoQ Revenue Growth

+15.5%

Cash Flow

Operating Cash Flow

-$45M

Free Cash Flow

-$76M

Stock-Based Comp.

$48M

Balance Sheet

Total Assets

$6.1B

Total Liabilities

$1.7B

Stockholders' Equity

$4.4B

Cash & Equivalents

$605M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$519M	$486M	+6.9%
Gross Profit	$402M	$366M	+10.0%
Operating Income	$137M	$25M	+447.4%
Net Income	$121M	$17M	+595.4%

Revenue Segments

Product

$506M97%

Royalty And Other

$14M3%